A new generation of DC-based immunotherapy targeting personal tumor antigens. Personal tumor antigens (e.g. neoantigens) have clinically demonstrated as promising targets for DC-based immunotherapy. Basing on above findings, we elaborated the treatment by platforms to increase personal tumor antigen presentation, and anti-tumor biomarker profiling. In addition, the manufacturing process is shorter. This innovation will significantly prolong both overall survival (OS) and progression-free survival (PFS) in refractory solid tumors such as brain tumor, liver cancer, and ovarian cancer.
We will launch CT101 in late 2019 dues to Taiwan Special Regulation of Cell Therapy.